Advertisement

Neurological Sciences

, Volume 37, Issue 2, pp 181–189 | Cite as

Aspirin resistance and other aspirin-related concerns

  • Gaoyu Cai
  • Weijun Zhou
  • Ya Lu
  • Peili Chen
  • Zhongjiao Lu
  • Yi FuEmail author
Review Article

Abstract

Aspirin is a widely used medication and has become a cornerstone for treating cardiovascular disease. Aspirin can significantly reduce the incidence of cardiovascular ischemic events, recurrence and mortality, thereby improving the long-term prognosis of patients. However, there has been a staggering increase in the volume of literature addressing the issue of so-called “aspirin resistance” in recent years, and for some patients, it is difficult to avoid adverse reactions to aspirin. In this review, we present both the historical aspects of aspirin use and contemporary developments in its clinical use.

Keywords

Aspirin Clinical use Resistance phenomenon Adverse effects 

Notes

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Campbell CL, Smyth S, Montalescot G, Steinhubl SR (2007) Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297:2018–2024CrossRefPubMedGoogle Scholar
  2. 2.
    Fuster V, Sweeny JM (2011) Aspirin: a historical and contemporary therapeutic overview. Circulation 123:768–778CrossRefPubMedGoogle Scholar
  3. 3.
    Patrono C, Baigent C, Hirsh J, Roth G (2008) American College of Chest Physicians: antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:199S–233SCrossRefPubMedGoogle Scholar
  4. 4.
    Hutt AJ, Caldwell J, Smith RL (1986) The metabolism of aspirin in man: a population study. Xenobiotica 16:239–249CrossRefPubMedGoogle Scholar
  5. 5.
    Dargan PI, Wallace CI, Jones AL (2002) An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J 19:206–209PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Nowak JZ (2014) Aspirin and age-related macular degeneration: positives versus negatives. Expert Opin Drug Saf 13:687–690PubMedGoogle Scholar
  7. 7.
    Aïd S, Bosetti F (2011) Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 93:46–51PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Félétou M, Huang Y, Vanhoutte PM (2011) Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 164:894–912PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9:259–267CrossRefPubMedGoogle Scholar
  10. 10.
    Cannon CP, Cannon PJ (2012) Physiology: COX-2 inhibitors and cardiovascular risk. Science 336:1386–1387CrossRefPubMedGoogle Scholar
  11. 11.
    Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120CrossRefPubMedGoogle Scholar
  12. 12.
    Schrör K (2011) Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol 25:473–484CrossRefPubMedGoogle Scholar
  13. 13.
    Yokoyama H, Ito N, Soeda S, Ozaki M, Suzuki Y, Watanabe M, Kashiwakura E, Kawada T, Ikeda N, Tokuoka K, Kitagawa Y, Yamada Y (2013) Prediction of antiplatelet effects of aspirin in vivo based on in vitro results. Clin Appl Thromb Hemost 19:600–607CrossRefPubMedGoogle Scholar
  14. 14.
    Park SJ, Oh IY, Kim KH (2011) Minimal withdrawal of dual antiplatelet agents under the guidance of a point-of-care platelet activity assay early after drug-eluting stent implantation for surgical removal of renal cell carcinoma. Int J Cardiol 149:e85–e87CrossRefPubMedGoogle Scholar
  15. 15.
    Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Antithrombotic Trialists’ (ATT) Collaboration: aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860CrossRefPubMedGoogle Scholar
  16. 16.
    CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 349:1641–1649CrossRefGoogle Scholar
  17. 17.
    International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569–1581CrossRefGoogle Scholar
  18. 18.
    Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N (2014) Low-dose aspirin for primary prevention of cardiovascular events in japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312:2510–2520CrossRefPubMedGoogle Scholar
  19. 19.
    Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD (2010) Aspirin for Asymptomatic Atherosclerosis Trialists: aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303:841–848CrossRefPubMedGoogle Scholar
  20. 20.
    Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Functional Genomics and Translational Biology, and Council on Hypertension, Council on Hypertension (2014) Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45:3754–3832CrossRefPubMedGoogle Scholar
  21. 21.
    Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A (2015) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26:47–57PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13:518–527CrossRefPubMedGoogle Scholar
  23. 23.
    Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379:1591–1601CrossRefPubMedGoogle Scholar
  24. 24.
    Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741–1750CrossRefPubMedGoogle Scholar
  25. 25.
    Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914–923PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Gasparyan AY, Watson T, Lip GY (2008) The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51:1829–1843CrossRefPubMedGoogle Scholar
  27. 27.
    Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R (2009) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30:426–435CrossRefPubMedGoogle Scholar
  28. 28.
    Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28:1702–1708CrossRefPubMedGoogle Scholar
  29. 29.
    Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230–235CrossRefPubMedGoogle Scholar
  30. 30.
    Kasmeridis C, Apostolakis S, Lip GY (2013) Aspirin and aspirin resistance in coronary artery disease. Curr Opin Pharmacol 13:242–250CrossRefPubMedGoogle Scholar
  31. 31.
    Ertugrul DT, Tutal E, Yildiz M, Akin O, Yalçin AA, Ure OS, Yilmaz H, Yavuz B, Deveci OS, Ata N, Küçükazman M (2010) Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab 95:2897–2901CrossRefPubMedGoogle Scholar
  32. 32.
    Shiotani A, Sakakibara T, Nomura M, Yamanaka Y, Nishi R, Imamura H, Tarumi K, Kamada T, Hata J, Haruma K (2010) Aspirin-induced peptic ulcer and genetic polymorphisms. J Gastroenterol Hepatol 25:S31–S34CrossRefPubMedGoogle Scholar
  33. 33.
    Pakala R, Waksman R (2011) Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovasc Revasc Med 12:312–322CrossRefPubMedGoogle Scholar
  34. 34.
    Tsui PY, Cheung CW, Lee Y, Leung SW, Ng KF (2015) The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primaryhaemostasis under influence of aspirin—a randomized controlled trial. BMC Anesthesiol 28:15–80Google Scholar
  35. 35.
    Paniccia R, Priora R, Liotta AA, Abbate R (2015) Platelet function tests: a comparative review. Vasc Health Risk Manag 11:133–148PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Dahlen JR, Price MJ, Parise H, Gurbel PA (2013) Evaluating the clinical usefulness of platelet function testing: considerations for the proper application andinterpretation of performance measures. Thromb Haemost 109:808–816CrossRefPubMedGoogle Scholar
  37. 37.
    Cattaneo M (2012) Mechanisms of variability in antiplatelet agents response. Thromb Res 130(Suppl 1):27–28CrossRefGoogle Scholar
  38. 38.
    Kovács EG, Katona E, Bereczky Z, Homoródi N, Balogh L, Tóth E, Péterfy H, Kiss RG, Edes I, Muszbek L (2013) New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack ofaspirin resistance among healthy individuals. Thromb Res 131:320–324CrossRefPubMedGoogle Scholar
  39. 39.
    Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davì G, Patrono C (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 53:667–677CrossRefPubMedGoogle Scholar
  40. 40.
    Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O’Brien J, Crean P, Shields DC, Fitzgerald DJ (2005) Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3:2340–2345CrossRefPubMedGoogle Scholar
  41. 41.
    Fan L, Cao J, Liu L, Li X, Hu G, Hu Y, Zhu B (2013) Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease. Gerontology 59:122–131CrossRefPubMedGoogle Scholar
  42. 42.
    Weng Z, Li X, Li Y, Lin J, Peng F, Niu W (2013) The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS One 8:e78093PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Sharma V, Kaul S, Al-Hazzani A, Alshatwi AA, Jyothy A, Munshi A (2013) Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis 35:95–99CrossRefPubMedGoogle Scholar
  44. 44.
    Ross S, Eikelboom J, Anand SS, Eriksson N, Gerstein HC, Mehta S, Connolly SJ, Rose L, Ridker PM, Wallentin L, Chasman DI, Yusuf S, Paré G (2014) Association of cyclooxygenase-2 genetic variant with cardiovascular disease. Eur Heart J 35:2242–2248aPubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont PJ (2006) Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 47:541–546CrossRefPubMedGoogle Scholar
  46. 46.
    Floyd CN, Ferro A (2014) The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol 77:446–457PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Abderrazek F, Chakroun T, Addad F, Dridi Z, Gerotziafas G, Gamra H, Hassine M, Elalamy I (2010) The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb Res 125:e265–e268CrossRefPubMedGoogle Scholar
  48. 48.
    Lordkipanidzé M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C (2011) Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res 128:47–53CrossRefPubMedGoogle Scholar
  49. 49.
    Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650–1655CrossRefPubMedGoogle Scholar
  50. 50.
    Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965CrossRefPubMedGoogle Scholar
  51. 51.
    Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008) Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336:195–198PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Meek IL, Vonkeman HE, Kasemier J, Movig KL, van de Laar MA (2013) Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69:365–371CrossRefPubMedGoogle Scholar
  53. 53.
    Arya V, Mahajan P, Saraf A, Mohanty A, Sawhney JP, Bhargava M (2015) Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with aspirin and ClopidogrelResistance in cohort of Indian patients with Coronary Artery Disease. Int J Lab Hematol. doi: 10.1111/ijlh.12416 PubMedGoogle Scholar
  54. 54.
    Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ (2012) GIFT Investigators: influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneouscoronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 59:1928–1937CrossRefPubMedGoogle Scholar
  55. 55.
    Choi H, Ryu J, Seo H, Kang M, Kim E (2015) Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? Int J Clin Pharm 37:758–761CrossRefPubMedGoogle Scholar
  56. 56.
    Wagner H, Angiolillo DJ, Ten Berg JM, Bergmeijer TO, Jakubowski JA, Small DS, Moser BA, Zhou C, Brown P, James S, Winters KJ, Erlinge D (2014) Higher body weight patients on clopidogrel maintenance therapy have lower active metaboliteconcentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weightpatients. J Thromb Thrombolysis 38:127–136PubMedGoogle Scholar
  57. 57.
    Lundström A, Wallén H, von Arbin M, Jörneskog G, Gigante B, Höeg Dembrower K, Laurencikas E, Laska AC (2015) Clopidogrel resistance after minor ischemic stroke or transient ischemic attack is associated with radiological cerebral small-vessel disease. J Stroke Cerebrovasc Dis 24:2348–2357CrossRefPubMedGoogle Scholar
  58. 58.
    Fifi JT, Brockington C, Narang J, Leesch W, Ewing SL, Bennet H, Berenstein A, Chong J (2013) Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 34:716–720CrossRefPubMedGoogle Scholar
  59. 59.
    Sostres C, Gargallo CJ, Arroyo MT, Lanas A (2010) Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 24:121–132CrossRefPubMedGoogle Scholar
  60. 60.
    Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM (2008) American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118:1894–1909CrossRefPubMedGoogle Scholar
  61. 61.
    Uemura N, Sugano K, Hiraishi H, Shimada K, Goto S, Uchiyama S, Okada Y, Origasa H, Ikeda Y (2014) MAGIC Study Group: risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol 49:814–824PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ (2005) Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 22:795–801CrossRefPubMedGoogle Scholar
  63. 63.
    García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S (2011) Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 123:1108–1115CrossRefPubMedGoogle Scholar
  64. 64.
    de Abajo FJ, Gil MJ, Bryant V, Timoner J, Oliva B, García-Rodríguez LA (2013) Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. Eur J Clin Pharmacol 69:691–701CrossRefPubMedGoogle Scholar
  65. 65.
    Cea Soriano L, Rodríguez LA (2010) Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol 1:126PubMedCentralCrossRefPubMedGoogle Scholar
  66. 66.
    Gorelick PB, Weisman SM (2005) Risk of hemorrhagic stroke with aspirin use: an update. Stroke 36:1801–1807CrossRefPubMedGoogle Scholar
  67. 67.
    Larrue V, von Kummer RR, Müller A, Bluhmki E (2001) Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32:438–441CrossRefPubMedGoogle Scholar
  68. 68.
    Patel B, Lawrence AJ, Chung AW, Rich P, Mackinnon AD, Morris RG, Barrick TR, Markus HS (2013) Cerebral microbleeds and cognition in patients with symptomatic small vessel disease. Stroke 44:356–361CrossRefPubMedGoogle Scholar
  69. 69.
    Cordonnier C, Al-Shahi Salman R, Wardlaw J (2007) Spontaneous brain microbleeds, systematic review, subgroup analyses and standards for study design and reporting. Brain 130:1988–2003CrossRefPubMedGoogle Scholar
  70. 70.
    Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, Breteler MM (2009) Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol 66:714–720CrossRefPubMedGoogle Scholar
  71. 71.
    Gregoire SM, Jäger HR, Yousry TA (2010) Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry 81:679–684CrossRefPubMedGoogle Scholar
  72. 72.
    Wong KS, Chan YL, Liu JY, Gao S, Lam WW (2003) Asymptomatic microbleeds as a risk factor for aspirin-associated intracerebral hemorrhages. Neurology 60:511–513CrossRefPubMedGoogle Scholar
  73. 73.
    Cordonnier C (2010) Brain microbleeds. Pract Neurol 10:94–100CrossRefPubMedGoogle Scholar
  74. 74.
    Mené P, Pugliese F, Patrono C (1995) The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease. Semin Nephrol 15:244–252PubMedGoogle Scholar
  75. 75.
    Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R (2000) The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 43:103–108CrossRefPubMedGoogle Scholar
  76. 76.
    Segal R, Lubart E, Leibovitz A, Iaina A, Caspi D (2006) Renal effects of low dose aspirin in elderly patients. Isr Med Assoc J 8:679–682PubMedGoogle Scholar
  77. 77.
    Szczeklik A, Stevenson DD (2003) Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111:913–921 (quiz 922) CrossRefPubMedGoogle Scholar
  78. 78.
    Jenkins C, Costello J, Hodge L (2004) Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 328:434PubMedCentralCrossRefPubMedGoogle Scholar
  79. 79.
    Hirata H, Arima M, Fukushima Y, Honda K, Sugiyama K, Tokuhisa T, Fukuda T (2011) Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma. Clin Exp Allergy 41:1133–1142CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2015

Authors and Affiliations

  • Gaoyu Cai
    • 1
  • Weijun Zhou
    • 2
  • Ya Lu
    • 3
  • Peili Chen
    • 2
  • Zhongjiao Lu
    • 1
  • Yi Fu
    • 1
    Email author
  1. 1.Department of Neurology and Institute of NeurologyRui Jin Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghaiChina
  2. 2.Department of EmergencyRui Jin Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghaiChina
  3. 3.Shanghai Wusong Street Community Health Service CenterShanghaiChina

Personalised recommendations